Skip to content

US · BIOA · BIOTECHNOLOGY

BioAge Labs Inc. (BIOA) intrinsic value and stock valuation

$4.28as of 2026-11-21 · Mkt cap 413.39M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioAge Labs Inc. DCF and intrinsic value

InvestorsCraft values BIOA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BIOA’s statements →

BioAge Labs Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Emeryville, CA 94608 bioagelabs.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$8.99M
20222025
Net income
-$-80.61M
20222025
Free cash flow
-$-82.35M
20222025
Total equity
$272.1M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$8.99M$0.00$0.00$0.00
Operating income-$-92.78M-$-78.19M-$-48.4M-$-39.97M
Net income-$-80.61M-$-71.11M-$-63.85M-$-39.72M
EPSd-$-2.24M-$-1.98M-$-1.87M-$-1.16M
Operating cash flow-$-81.63M-$-51.52M-$-37.36M-$-36.18M
Capital expenditure-$-720K-$-370K-$-170K-$-100K
Free cash flow-$-82.35M-$-51.89M-$-37.53M-$-36.28M
Total assets$294.9M$358.2M$25.9M$28.4M
Total debt$5.56M$8.7M$53.3M$2.47M
Net debt-$-183.33M-$-345.64M$31.6M-$-25.18M
Total equity$272.1M$323.1M-$-173.4M-$-112.56M
Cash and short-term investments$281.1M$354.4M$21.6M$27.6M
Income statement
2025202420232022
Revenue$8.99M$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$8.99M$0.00$0.00$0.00
Research and development expenses$74M$59M$33.9M$30.5M
Selling, general and administrative expenses$27.8M$19.2M$14.5M$9.45M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$101.8M$78.2M$48.4M$40M
Cost and expenses$101.8M$78.2M$48.4M$40M
Interest income$13.1M$9.63M$2.43M$470K
Interest expense$700K$2.37M$7.79M$240K
Depreciation and amortization$210K$170K$160K$130K
Ebitda-$-79.69M-$-68.58M-$-55.9M-$-39.35M
Operating income-$-92.78M-$-78.19M-$-48.4M-$-39.97M
Total other income/expenses, net$12.2M$7.08M-$-15.45M$250K
Income before tax-$-80.61M-$-71.11M-$-63.85M-$-39.72M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-80.61M-$-71.11M-$-63.85M-$-39.72M
Weighted average shares outstanding$35.9M$35.9M$34.2M$34.2M
Weighted average diluted shares outstanding$35.9M$35.9M$34.2M$34.2M
Balance sheet
2025202420232022
Cash and short-term investments$281.1M$354.4M$21.6M$27.6M
Net receivables$770K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$286.8M$357.1M$25.3M$28M
Property, plant and equipment, net$3.75M$790K$520K$370K
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$100K$100K$100K$0.00
Total non-current assets$8.1M$1.13M$620K$400K
Total assets$294.9M$358.2M$25.9M$28.4M
Accounts payable$2.67M$2M$1.87M$2.26M
Short-term debt$3.23M$6.2M$45.1M$220K
Deferred revenue$5.75M$7.83M$3.31M$0.00
Total current liabilities$20.1M$27.8M$58.2M$5.86M
Long-term debt$2.33M$2.5M$8.2M$2.25M
Deferred revenue, non-current$0.00$4.67M$0.00$0.00
Total non-current liabilities$2.7M$7.33M$141.2M$135.1M
Capital lease obligations$580K$200K$190K$50K
Total liabilities$22.8M$35.1M$199.3M$141M
Common stock$0.00$0.00$0.00$0.00
Retained earnings-$-333.42M-$-252.81M-$-181.7M-$-117.85M
Accumulated other comprehensive income (loss)$280K$240K$160K$170K
Total equity$272.1M$323.1M-$-173.4M-$-112.56M
Total investments$92.3M$100K$100K$0.00
Total debt$5.56M$8.7M$53.3M$2.47M
Net debt-$-183.33M-$-345.64M$31.6M-$-25.18M
Cash flow statement
2025202420232022
Net income-$-80.61M-$-71.11M-$-63.85M-$-39.72M
Depreciation and amortization$210K$170K$160K$130K
Stock-based compensation$11.7M$6.98M$3.02M$2.54M
Change in working capital-$-11.83M$11.2M$6.71M$800K
Accounts receivable-$-770K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$790K$10K-$-390K$990K
Net cash provided by operating activities-$-81.63M-$-51.52M-$-37.36M-$-36.18M
Investments in property, plant and equipment-$-720K-$-370K-$-170K-$-100K
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-95.22M-$-370K-$-270K-$-100K
Common stock issued$17.9M$221.6M$0.00$40K
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.5M$381.2M$34.9M$2.5M
Net change in cash-$-165.46M$329.4M-$-2.69M-$-33.54M
Cash at end of period$188.9M$354.4M$25M$27.6M
Operating cash flow-$-81.63M-$-51.52M-$-37.36M-$-36.18M
Capital expenditure-$-720K-$-370K-$-170K-$-100K
Free cash flow-$-82.35M-$-51.89M-$-37.53M-$-36.28M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioAge Labs Inc.

        BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

        CEO
        Kristen Fortney
        Employees
        62
        Beta
        0.93

        Explore

        Frequently asked questions

        What is the intrinsic value of BioAge Labs Inc. (BIOA)?

        InvestorsCraft does not currently publish an intrinsic value for BIOA. How the IC value is calculated.

        Is BIOA undervalued?

        InvestorsCraft does not publish an undervaluation signal for BIOA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.